Brickell is the financial capital of Latin American trade — the banks that finance Miami’s imports, the regional headquarters that direct them, and the executives who make product and market-entry decisions for the hemisphere all sit within a few blocks. Garg Law’s Miami office is here, at 1221 Brickell Avenue, in the middle of that corridor. That concentration of regulated commerce is why Garg Law brings its FDA and customs practice to Brickell businesses from a Miami office on Brickell Avenue — close enough to the port, the airport and the agencies to act the day a problem surfaces. The companies steering FDA-regulated product lines from Brickell towers need regulatory answers at deal speed — and the office handling them is on the same street.
Understanding OTC drug compliance matters
Most over-the-counter drugs reach market through the OTC monograph system: FDA’s category-by-category rulebooks (sunscreens, antacids, hand sanitizers, analgesics, and dozens more) fixing which active ingredients, strengths, indications and label statements are permitted. A product matching its monograph needs no application; one deviating from it — a novel ingredient, an unlisted claim — is an unapproved new drug, full stop.
The operational regime is drug-grade: facility registration and drug listing (with NDC numbers), cGMP manufacturing compliance, the standardized Drug Facts label, and — since the CARES Act reformed the monograph system — OMUFA user fees for manufacturers. Foreign facilities need U.S. agents and face FDA inspection like domestic ones.
Import screening is where OTC compliance gets tested for Miami’s trade: entries from unregistered facilities, products with unlisted formulations, sunscreen and sanitizer shipments with monograph deviations, and cosmetics making drug claims all show up as holds, detentions and import-alert candidates. The hand-sanitizer era put entire foreign facility rosters on alert lists — many remain there.
Acting early vs. waiting: what it costs
OTC enforcement is unforgiving because the standards are written down: a monograph deviation is not a judgment call FDA has to argue, it is a checkbox. Unapproved-drug status invalidates inventory wholesale, import alerts on OTC categories persist for years, and cGMP failures at a supplier can cut off a product line overnight.
The engagement, step by step
- Monograph analysis: does each formulation, dose and claim fit its monograph — and what changes if not
- Registration and listing compliance for every facility and product, with NDC and renewal management
- Drug Facts labeling and claims review, including the cosmetic/drug combination products Miami imports heavily
- Import compliance: supplier facility verification, entry data, and detention response for flagged entries
- cGMP and inspection readiness — 483 responses, warning-letter strategy and corrective-action programs
Five mistakes that sink these matters
- Marketing a “cosmetic” with drug claims instead of running it through the monograph analysis
- Importing from facilities that never registered or listed — the entry screen catches it
- Tweaking a monograph formulation for marketing differentiation and creating an unapproved new drug
- Drug Facts labels that omit or reorder required elements
- Assuming legacy hand-sanitizer-era suppliers came off import alerts — many did not
OTC Drug Compliance Lawyer services for Brickell
The work around Brickell — international banking and trade finance, multinational regional headquarters, consumer brand offices, legal and professional services, import/export holding companies — is FDA-regulated at nearly every turn, and matters here move on Miami’s financial district, home to the banks, trade finance desks and regional headquarters that fund and direct hemispheric trade. Garg Law's Miami office is at 1221 Brickell Avenue, and the practice was built for exactly this market: founder Shelly Garg spent years counseling importers at the world's largest dedicated international trade law firm before opening her own, and works at the crossroads of FDA and CBP compliance for foreign and domestic companies across the food, beverage, supplement, cosmetics, OTC drug and medical device industries.
Frequently asked questions
Do OTC drugs need FDA approval?
Not individually — if they conform to the applicable OTC monograph in ingredients, strength, indications and labeling, and are made in registered, listed, cGMP-compliant facilities. Products outside a monograph need an approved application; selling them without one is marketing an unapproved new drug.
What is a Drug Facts label and is it mandatory?
Yes — the standardized panel (active ingredients, purposes, uses, warnings, directions, inactive ingredients) with prescribed content and order for OTC drugs. Formatting deviations are labeling violations FDA and the import screen both flag.
Is my product a cosmetic or an OTC drug?
Claims decide: a moisturizer is a cosmetic; a moisturizer “with SPF” is a drug (sunscreen monograph); an antiperspirant is a drug while a deodorant is a cosmetic. Combination cosmetic-drugs must satisfy both regimes — a constant issue in Miami’s beauty import trade.
Why are OTC imports from certain factories always detained?
Import alerts. Facilities with cGMP findings, refused inspections or violative samples get listed for detention without physical examination — the sanitizer boom added hundreds. Sourcing decisions should check alert lists first; removal petitions exist but take documented time.
What are OMUFA fees and who pays them?
The OTC Monograph User Fee program funds FDA’s modernized monograph system through annual facility fees on OTC drug manufacturers. Unpaid fees have consequences — including products from unpaid facilities being deemed misbranded. Fee status belongs on the compliance calendar like registration renewals.